Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
197
Completed, industry sponsors, Gastroenterology and liver, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed197
197 trials
Showing 1 to 25, recently updated first.
- A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive DysfunctionPivotal-lookingCompleted
Umecrine Cognition ABIndustry
NCT07304843 · 207 participants · Start Apr 14, 2023 · Primary completion Sep 9, 2026
Drug: golexanolone; golexanolone and 3 more · For: Primary Biliary Cholangitis (PBC)
Sites: Düsseldorf, Germany; Leipzig, Germany; Athens, Greece · 38 sites in all
Corcept TherapeuticsIndustry
NCT07553663 · 14 participants · Start Apr 30, 2026 · Primary completion Sep 22, 2026
Drug: Miricorilant · For: Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis; Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and 1 more
Sites: San Antonio, Texas
- A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male SubjectsCompleted
AstraZenecaAstraZeneca (AZN)
NCT02612662 · 40 participants · Start Nov 24, 2015 · Primary completion Nov 4, 2017
Drug: AZD4076; Placebo · For: Non-alcoholic Steatohepatitis (NASH)
Sites: Brooklyn, Maryland
Corcept TherapeuticsIndustry
NCT06947304 · 9 participants · Start Aug 22, 2025 · Primary completion Aug 13, 2026
Drug: Miricorilant · For: Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH); Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and 1 more
Sites: Columbia, Missouri
GlaxoSmithKlineGSK (GSK)
NCT07335198 · 30 participants · Start Mar 5, 2026 · Primary completion Aug 13, 2026
Drug: Efimosfermin alfa; Placebo · For: Non-alcoholic Fatty Liver Disease
Sites: Auckland, New Zealand
Cinclus Pharma Holding ABIndustry
NCT03105375 · 39 participants · Start Feb 21, 2017 · Primary completion Oct 12, 2017
Drug: Single ascending dose of X842; Multiple ascending dose of X842 and 1 more · For: Healthy Volunteers
Sites: Uppsala, Sweden
AQILION ABIndustry
NCT07093008 · 9 participants · Start Jun 13, 2025 · Primary completion Jul 16, 2025
Drug: AQ280 Capsule; AQ280 Tablet for Oral Suspension and 2 more · For: Eosinophilic Esophagitis
Sites: Madison, Wisconsin
Gilead SciencesGilead Sciences (GILD)
NCT04950764 · 24 participants · Start Nov 16, 2021 · Primary completion Feb 24, 2025
Drug: Seladelpar · For: Primary Biliary Cholangitis; Compensated Cirrhosis; Hepatic Impairment
Sites: Chandler, Arizona; Sacramento, California; Aurora, Colorado · 20 sites in all
COUR Pharmaceutical Development Company, Inc.Industry
NCT05104853 · 42 participants · Start Jan 25, 2022 · Primary completion Jan 30, 2026
Drug: CNP-104; Placebo · For: Primary Biliary Cholangitis
Sites: Coronado, California; Lancaster, California; Sacramento, California · 19 sites in all
- A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of AmoxicillinCompleted
Cinclus Pharma Holding ABIndustry
NCT07308041 · 12 participants · Start Nov 11, 2025 · Primary completion Dec 22, 2025
Drug: Drug Drug Interaction · For: Drug Interaction; GERD (Gastroesophageal Reflux Disease); Safety, and Tolerability
Sites: Uppsala, Sweden
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT06716905 · 72 participants · Start Mar 6, 2025 · Primary completion Sep 22, 2025
Drug: ACT500 tablets; Placebo and 2 more · For: Non-alcoholic Steatohepatitis
Sites: Wuhan, China
Daewon Pharmaceutical Co., Ltd.Industry
NCT07364838 · 24 participants · Start Nov 21, 2024 · Primary completion Apr 8, 2025
Drug: DW4421 · For: GERD (Gastroesophageal Reflux Disease)
Sites: Cheongju-si, South Korea
Phathom Pharmaceuticals, Inc.Industry
NCT06831344 · 25 participants · Start Feb 14, 2025 · Primary completion Apr 5, 2025
Drug: Vonoprazan ODT-1 or ODT-2 without Water; Vonoprazan ODT-1 or ODT-2 with Water and 1 more · For: Healthy Volunteers
Sites: Austin, Texas
- Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy MalesPivotal-lookingCompleted
J2H BiotechIndustry
NCT06308861 · 100 participants · Start Aug 12, 2020 · Primary completion Jun 25, 2021
Drug: Single administration Amg dose Group; Single administration Bmg dose Group and 18 more · For: Non-alcoholic Steatohepatitis
Sites: Suwon, South Korea
J2H BiotechIndustry
NCT06308874 · 16 participants · Start Jan 2, 2023 · Primary completion Feb 17, 2023
Drug: Amg dose administration group; Amg dose administration group- Placebo and 2 more · For: Non-alcoholic Steatohepatitis
Sites: Suwon, South Korea
Boehringer IngelheimBoehringer Ingelheim
NCT05970640 · 64 participants · Start Aug 14, 2023 · Primary completion Oct 31, 2024
Drug: BI 3006337; Placebo matching BI 3006337 · For: Non-alcoholic Fatty Liver Disease; Obesity
Sites: Chula Vista, California; La Mesa, California; Montclair, California · 12 sites in all
Parvus Therapeutics, Inc.Industry
NCT06798454 · 24 participants · Start Oct 15, 2024 · Primary completion Apr 23, 2025
Drug: PVT201 · For: Primary Biliary Cholangitis (PBC)
Sites: Adelaide, Australia
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06052566 · 22 participants · Start Nov 21, 2023 · Primary completion Dec 5, 2024
Drug: Efinopegdutide · For: Non-alcoholic Steatohepatitis; Hepatic Impairment
Sites: Miami, Florida; Tampa, Florida; San Antonio, Texas · 4 sites in all
Arrowhead PharmaceuticalsIndustry
NCT04202354 · 50 participants · Start Mar 3, 2020 · Primary completion Sep 3, 2021
Drug: ARO-HSD Injection; sterile normal saline (0.9% NaCl) · For: Non-alcoholic Steatohepatitis
Sites: Grafton, New Zealand
Jiangsu Sinorda Biomedicine Co., LtdIndustry
NCT07107672 · 6 participants · Start Jun 15, 2022 · Primary completion Jul 7, 2022
Drug: [14C]X842 · For: Gastroesophageal Reflux Disease
Sites: Bengbu, China
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06024408 · 9 participants · Start May 21, 2024 · Primary completion Jul 7, 2025
Drug: ALN-PNP; Placebo · For: Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH); Genetic Risk Factor
Sites: Cheongju-si, South Korea; Seongnam-si, South Korea; Seoul, South Korea · 5 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05560607 · 19 participants · Start Aug 12, 2022 · Primary completion Nov 20, 2023
Drug: AZD7503 Intervention · For: Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD and 3 more
Sites: San Antonio, Texas
AstraZenecaAstraZeneca (AZN)
NCT05107336 · 44 participants · Start Nov 25, 2021 · Primary completion Mar 21, 2023
Drug: AZD2693; Placebo · For: Healthy Participants
Sites: Sumida-ku, Japan
AstraZenecaAstraZeneca (AZN)
NCT05294458 · 10 participants · Start Mar 28, 2022 · Primary completion Sep 12, 2022
Drug: cotadutide solution for injection · For: Non-alcoholic Steatohepatitis; Type 2 Diabetes Mellitus (T2DM); Chronic Kidney Disease
Sites: Ruddington, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT06093542 · 12 participants · Start Oct 25, 2023 · Primary completion Mar 20, 2024
Drug: AZD7053; Placebo · For: Heathy Participants
Sites: Sumida-ku, Japan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.